Biocon gets DCGI nod for CytoSorb use in critical Covid-19 cases

Biocon said its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro- inflammatory cytokines levels in confirmed ovid-19 patients admitted to ICU with confirmed or imminent respiratory failure.